The global primaquine market is expected to grow at a moderate CAGR during the forecast period (2021-2027). Primaquine is an antimalarial drug that is also used to treat pneumocystis pneumonia. It is used to treat malaria caused by Plasmodium vivax and Plasmodium ovale. It is used in conjunction with clindamycin to treat Pneumocystis pneumonia. It is administered orally. The FDA originally authorized primaquine in 1946. It is on the WHO's List of Essential Medications, which includes the safest and most effective medicines required in a health system. It can also be purchased as a generic drug.

Free Sample Copy @ https://www.omrglobal.com/request-sample/primaquine-market

Primaquine is primarily used to prevent Plasmodium vivax and Plasmodium ovale malaria recurrence. Patients with confirmed P. vivax or P. ovale infection who do not get primaquine face a high risk of recurrence for weeks or months (sometimes years). In regions nearing malaria eradication or confronting artemisinin resistance, the World Health Organization (WHO) recommends using the medication primaquine in combination with artemisinin-based combination treatment (ACT) to prevent Plasmodium falciparum transmission. The rise in malaria incidence in developing nations is a significant factor driving the growth of the primaquine. Furthermore, increased government awareness campaigns and increased research for novel antimalarial medicines are some of the causes driving the market growth.

A Full Report of Global Primaquine Market is Available at:
https://www.omrglobal.com/industry-reports/primaquine-market

Primaquine is used to treat pneumocystis pneumonia (PCP), a fungal infection that affects patients with AIDS and, less often, those on immunosuppressive medications. PCP is frequently coupled with clindamycin to treat it successfully. According to National Center for Biotechnology Information (NCBI), the prevalence of PCP without chemoprophylaxis, in transplant patients range from 5% to 25%, in patients with collagen vascular disease from 2% to 6%, and in cancer patients from 1% to 25%. CD4+ lymphocyte defects are a major risk factor for PCP, although the immunological response to Pneumocystis is complicated. Thus, the rising prevalence of PCP is expected to drive the adoption of primaquine during the forecast period.

Global Primaquine Market – Segmentation
By Product Type
Injectables
Capsules
Tablets
By Application
Malaria
Pneumocystis Pneumonia
By Distribution Channel
Hospitals and Clinics
Online Drug Stores
Others

Global Primaquine Market – Segmentation by Region 
North America 
United States
Canada
Europe
Germany
United Kingdom
France
Spain
Italy
Rest of Europe
Asia-Pacific 
China
Japan
India
Rest of Asia-Pacific
Rest of the World

Company Profiles
Cyper Pharma
Pfizer Inc.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/primaquine-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected] 
Contact no: +91 780-304-0404